Moderna疫苗即将获得紧急授权使用，但专业人士预计其估值可能面临风险

食品和药物管理局将在周四，就是否批准Moderna的疫苗展开小组讨论，不久之后该疫苗很可能获得监管部门的批准。但是Moderna股价在周三开盘时跌幅高达8.8%，至每股134.31美元。

分析人士认为，Moderna疫苗即将被批准，但是随着散户兴趣减弱，Moderna的估值可能面临风险。辉瑞公司（Pfizer Inc.）作为新冠疫苗的另一个领跑者，在过去的六个交易日里已经抛售了大约11%。

Moderna’s shot will face a Food and Drug Administration panel on Thursday, and soon after the vaccine is likely to get regulatory clearance. The stock fell as much as 8.8% to $134.31 per share at the open on Wednesday.

Moderna’s valuation may be at risk if retail interest wanes as new vaccines become a reality. Pfizer Inc., the other frontrunner in the search for a shot, has sold off roughly 11% in the past six trading days.   source

指尖新闻：高信噪比，一目了然

新冠疫情追踪